KING OF PRUSSIA, Pa.,
July 17, 2013 /PRNewswire/ --
Trevena, Inc., (Trevena) a clinical stage pharmaceutical company
and the leader in the discovery and development of G-protein
coupled receptor (GPCR) biased ligands, announced today that the
United States Patent and Trademark Office has granted Trevena a
composition of matter patent covering its development product
TRV027. United States Patent No. 8,486,885 entitled
"Beta-Arrestin Effectors and Composition and Methods of Use
Thereof," is expected to provide coverage for TRV027 until at least
July 2031.
TRV027 is an experimental intravenous drug for the treatment of
acute decompensated heart failure (ADHF), currently in mid-stage
clinical trials. It is a novel beta-arrestin biased ligand of
the angiotensin II type 1 receptor that combines the proven
benefits of angiotensin blockade with new beta-arrestin-mediated
biology to preserve cardiac and renal function. Trevena
recently entered into a collaborative licensing option agreement
for the development of TRV027 with Forest Laboratories Inc.
(NYSE:FRX). The company expects to commence a 500-patient
multi-center Phase 2b clinical trial for TRV027 in ADHF patients by
year end.
"This core patent provides the foundation for broad and
enforceable intellectual property protection for TRV027, and is
followed by a series of patent applications made by Trevena to
protect our growing pipeline of GPCR biased ligands in key markets
around the world," said Maxine
Gowen, Trevena's President and Chief Executive
Officer. David Solomon,
Forest's SVP of Corporate Development & Strategic Planning, and
a Board member at Trevena, added, "This issued patent enhances the
value potential of TRV027, and provides an essential platform from
which to drive its commercialization."
Trevena recently presented the results of a Phase 2a study on
the hemodynamic effects of TRV027 in patients with advanced heart
failure with reduced ejection fraction (NCT01187836), as a
poster at the American College of Cardiology meeting in
March 2013. The Phase 2a trial was an
ascending dose titration study in patients with stable NYHA Class 3
or 4 heart failure.
About ADHF
The American Heart Association estimates
that ADHF hospitalization costs the U.S. healthcare system more
than $20 billion each year in direct
spending. ADHF is already the leading reason for
hospitalization of individuals over 65 years old in the United States, with more than 1 million
hospital admissions per year. ADHF is also the most costly
diagnosis for Medicare in the nation. Despite the
significance of this problem, current therapies are not producing
meaningful improvements in patient outcomes. ADHF incidence
is increasing globally, and both heart failure mortality and
hospital re-admission following an ADHF event remain extremely
high.
About Trevena
Trevena, Inc. is a clinical stage
pharmaceutical company focused on discovering and developing the
next generation of GPCR targeted medicines. GPCRs are the
targets for at least one-third of modern medicinal products, and
remain the predominant class of targets under clinical evaluation.
Trevena's expertise lies in engineering "biased ligands" that
activate only the beneficial signaling pathways downstream of a
GPCR to unlock new biology and avoid drug adverse effects. In
addition to TRV027, Trevena's pipeline currently includes a
clinical stage mu-opioid biased ligand for post-operative pain, and
earlier-stage programs for chronic pain, and Parkinson's disease.
For more details, visit www.Trevenainc.com.
About Forest Laboratories
Forest Laboratories' (NYSE:
FRX) longstanding global partnerships and track record developing
and marketing pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal and pain management medicine. Forest's
pipeline, the most robust in its history, includes product
candidates in all stages of development across a wide range of
therapeutic areas. The Company is headquartered in
New York, NY. To learn more,
visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no
obligation to update forward-looking statements contained in this
release to reflect new information or future events or
developments.
For more information, please contact:
Rosamond Deegan, Vice President,
Business Development 610-354-8840 x225 (Corporate Inquiries)
Kimberly Minarovich, Christensen,
917-533-3268 (Media Inquiries)
SOURCE Trevena, Inc.